nach oben

Erschienen in:

01.06.2012 | Original Research

Quality of life in patients with brain metastases using the EORTC QLQ-BN20 and QLQ-C30

verfasst von: Emily Chen, Janet Nguyen, Liying Zhang, Liang Zeng, Lori Holden, Natalie Lauzon, Gillian Bedard, Kaitlin Koo, Alex Mingay, Cyril Danjoux, Arjun Sahgal, May Tsao, Elizabeth Barnes, Edward Chow

Erschienen in: Journal of Radiation Oncology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Given the poor life expectancy of the majority of patients with brain metastases, quality of life (QOL) endpoints are especially valuable to assess in this population. The present study assessed QOL in patients with brain metastases before and after treatment for their disease.

Methods

The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and the EORTC Brain Cancer Module (EORTC QLQ-BN20) questionnaire were administered to assess the QOL of patients with brain metastases before and 1 month after treatment. Linear regression analysis was applied to assess changes in QOL scores over time and to examine associations between the QLQ-BN20 and QLQ-C30 scales, patient demographics and clinical variables. Associations between the QLQ-BN20 and QLQ-C30 scales were evaluated using Spearman correlation.

Results

There were 47 patients assessed at baseline, 31 (67%) completed follow-up at 1 month post-treatment. The majority (81%) of patients received whole-brain radiotherapy only. Future uncertainty (QLQ-BN20) and fatigue (QLQ-C30) were the most prominent symptoms at baseline. Most QLQ-BN20 and QLQ-C30 scales did not significantly change from baseline to follow-up with the exception of hair loss (p = 0.0004) and itchy skin (p < 0.0001), which worsened post-treatment. Baseline KPS was positively correlated with QLQ-C30 physical functioning scale but negatively correlated to QLQ-BN20 motor dysfunction (p = 0.016), hair loss (p = 0.013) and leg weakness (p = 0.015) as well as QLQ-C30 pain (p = 0.042) and appetite loss (p = 0.030).

Conclusion

The maintenance of nearly all QOL scores 1 month after treatment indicates the treatment intervention likely played a symptom-stabilizing role and prevented QOL deterioration in the palliative setting.

Chamberlain MC (2010) Brain metastases: a medical neuro-oncology perspective. Expert Rev Neurother 10:563–573PubMedCrossRef

Sperduto PW et al (2010) Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 77:655–661PubMedCrossRef

Schouten LJ, Rutten J, Huveneers HA et al (2002) Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94:2698–2705PubMedCrossRef

Barnholtz-Sloan JS, Sloan AE, Davis FG et al (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22:2865–2872PubMedCrossRef

Posner JB (1977) Management of central nervous system metastasis. Semin Oncol 4:81–91PubMed

Lohr F, Pirzkall A, Hof H et al (2001) Adjuvant treatment of brain metastases. Semin Surg Oncol 6:543–551

Chao JH, Phillips R, Nickson JJ (1954) Roentgen-ray therapy of cerebral metastases. Cancer 7(4):682–689PubMedCrossRef

Zimm S, Wampler GL, Stablein D et al (1981) Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer 48(2):384–394PubMedCrossRef

Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376PubMedCrossRef

10.

Osoba D, Aaronson NK, Muller M et al (1996) The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res 5:139–150PubMedCrossRef

11.

Taphoorn MJ, Claassens L, Aaronson NK et al (2010) An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer 46:1033–1040PubMedCrossRef

12.

Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A et al (2001) The EORTC QLQ-C30 scoring manual, 3rd edn. European Organisation for Research and Treatment of Cancer, Brussels

13.

Kirkbride P, Tannock IF (2008) Trials in palliative treatment—have the goal posts been moved? Lancet Oncol 9:186–187PubMedCrossRef

14.

Wong J, Hird A, Zhang L et al (2009) Symptoms and quality of life in cancer patients with brain metastases following palliative radiotherapy. Int J Radiat Oncol Biol Phys 75(4):1125–1131PubMedCrossRef

15.

Roos DE, Wirth A, Burmeister BH et al (2006) Whole brain irradiation following surgery or radiosurgery for solitary brain metastases: Mature results of a prematurely closed randomized Trans-Tasman Radiation Oncology Group trial (TROG 98.05). Radiother Oncol 80(3):318–322PubMedCrossRef

16.

Addeo R, Caraglia M, Faiola V, Kirkbride P, Tannock IF (2008) Trials in palliative treatment—have the goal posts been moved? Lancet Oncol 9:186–187CrossRef

17.

Scott C, Suh J, Stea B, Nabid A, Hackman J (2007) Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (Efaproxyn) plus whole brain radiation therapy for brain metastases. Am J Clin Oncol 30:580–587PubMedCrossRef

18.

Yaneva MP, Semerdjieva MA (2006) Assessment of the effect of palliative radiotherapy for cancer patients with intracranial metastases using EORTC-QOL-C30 questionnaire. Folia Medica 48:23–29PubMed

19.

Chow E, Davis L, Holden L, Tsao M, Danjoux C (2005) Prospective assessment of patient-rated symptoms following whole brain radiotherapy for brain metastases. J Pain Symptom Manag 30:18–23CrossRef

20.

Bezjak A, Adam J, Barton R et al (2002) Symptom response after palliative radiotherapy for patients with brain metastases. Eur J Cancer 38:487–496PubMedCrossRef

21.

Steinmann D, Schafer C, van Oorschot B et al (2009) Effects of radiotherapy for brain metastases on quality of life (QoL). Prospective pilot study of the DEGRO QoL working party. Strahlenther Onkol 185:190–197PubMedCrossRef

22.

Gerrard GE, Prestwich RJ, Edwards A et al (2003) Investigating the palliative efficacy of whole-brain radiotherapy for patients with multiple-brain metastases and poor prognostic features. Clin Oncol 15:422–428CrossRef

23.

Doyle M, Bradley NM, Li K et al (2007) Quality of life in patients with brain metastases treated with a palliative course of whole-brain radiotherapy. J Palliat Med 10(2):367–374PubMedCrossRef

24.

Wong J, Hird A, Kirou-Mauro A, Napolskikh J, Chow E (2008) Quality of life in brain metastases radiation trials: a literature review. Curr Oncol 15(5):25–45PubMedCrossRef

Titel: Quality of life in patients with brain metastases using the EORTC QLQ-BN20 and QLQ-C30
verfasst von: Emily Chen
Janet Nguyen
Liying Zhang
Liang Zeng
Lori Holden
Natalie Lauzon
Gillian Bedard
Kaitlin Koo
Alex Mingay
Cyril Danjoux
Arjun Sahgal
May Tsao
Elizabeth Barnes
Edward Chow
Publikationsdatum: 01.06.2012
Verlag: Springer-Verlag
Erschienen in: Journal of Radiation Oncology / Ausgabe 2/2012
Print ISSN: 1948-7894
Elektronische ISSN: 1948-7908
DOI: https://doi.org/10.1007/s13566-012-0016-0

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Quality of life in patients with brain metastases using the EORTC QLQ-BN20 and QLQ-C30